[1] Connolly JJ, Ooka K, Lim JK. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials. J Clin Transl Hepatol, 2018, 6: 264-275.
[2] Harrison SA, Goodman Z, Jabbar A, et al. A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis. J Hepatol, 2020, 72: 816-827.
[3] Garcia-Tsao G, Bosch J, Kayali Z, et al. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension. J Hepatol, 2020, 72: 885-895.
[4] Harrison SA, Wong VW, Okanoue T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol, 2020, 73: 26-39.
[5] Thiagarajan P, Aithal GP. Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges. J Clin Exp Hepatol, 2019, 9: 515-521.
[6] Loomba R, Lawitz E, Mantry PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology, 2018, 67: 549-559.
[7] Anstee QM, Lawitz EJ, Alkhouri N, et al. Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. Hepatology, 2019, 70: 1521-1530.
[8] Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease(NAFLD)activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology, 2011, 53: 810-820.
[9] Chalasani N, Abdelmalek MF, Garcia-Tsao G, et al. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension. Gastroenterology, 2020, 158: 1334-1345.
[10] Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, 2019, 394: 2184-2196. |
